Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

5,235 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Circulating endothelial-derived activated microparticle: a useful biomarker for predicting one-year mortality in patients with advanced non-small cell lung cancer.
Wang CC, Tseng CC, Hsiao CC, Chang HC, Chang LT, Fang WF, Leu S, Wang YH, Tsai TH, Yang CT, Chen CH, Yip HK, Ho CK, Lin MC. Wang CC, et al. Among authors: wang yh. Biomed Res Int. 2014;2014:173401. doi: 10.1155/2014/173401. Epub 2014 Jun 29. Biomed Res Int. 2014. PMID: 25061601 Free PMC article. Clinical Trial.
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment Response in Advanced Lung Adenocarcinomas with G719X/L861Q/S768I Mutations.
Chiu CH, Yang CT, Shih JY, Huang MS, Su WC, Lai RS, Wang CC, Hsiao SH, Lin YC, Ho CL, Hsia TC, Wu MF, Lai CL, Lee KY, Lin CB, Yu-Wung Yeh D, Chuang CY, Chang FK, Tsai CM, Perng RP, Chih-Hsin Yang J. Chiu CH, et al. Among authors: wang cc. J Thorac Oncol. 2015 May;10(5):793-799. doi: 10.1097/JTO.0000000000000504. J Thorac Oncol. 2015. PMID: 25668120 Free article.
Baseline and Trend of Lymphocyte-to-Monocyte Ratio as Prognostic Factors in Epidermal Growth Factor Receptor Mutant Non-Small Cell Lung Cancer Patients Treated with First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.
Chen YM, Lai CH, Chang HC, Chao TY, Tseng CC, Fang WF, Wang CC, Chung YH, Wang YH, Su MC, Huang KT, Chen HC, Chang YC, Lin MC. Chen YM, et al. Among authors: wang cc, wang yh. PLoS One. 2015 Aug 27;10(8):e0136252. doi: 10.1371/journal.pone.0136252. eCollection 2015. PLoS One. 2015. PMID: 26313661 Free PMC article.
Baseline, Trend, and Normalization of Carcinoembryonic Antigen as Prognostic Factors in Epidermal Growth Factor Receptor-Mutant Nonsmall Cell Lung Cancer Patients Treated With First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.
Chen YM, Lai CH, Chang HC, Chao TY, Tseng CC, Fang WF, Wang CC, Chung YH, Huang KT, Chen HC, Chang YC, Lin MC. Chen YM, et al. Among authors: wang cc. Medicine (Baltimore). 2015 Dec;94(50):e2239. doi: 10.1097/MD.0000000000002239. Medicine (Baltimore). 2015. PMID: 26683939 Free PMC article.
Antacid Use and De Novo Brain Metastases in Patients with Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Who Were Treated Using First-Line First-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.
Chen YM, Lai CH, Chang HC, Chao TY, Tseng CC, Fang WF, Wang CC, Chung YH, Wang YH, Su MC, Liu SF, Huang KT, Chen HC, Chang YC, Lin MC. Chen YM, et al. Among authors: wang cc, wang yh. PLoS One. 2016 Feb 19;11(2):e0149722. doi: 10.1371/journal.pone.0149722. eCollection 2016. PLoS One. 2016. PMID: 26894507 Free PMC article.
The impact of clinical parameters on progression-free survival of non-small cell lung cancer patients harboring EGFR-mutations receiving first-line EGFR-tyrosine kinase inhibitors.
Chen YM, Lai CH, Chang HC, Chao TY, Tseng CC, Fang WF, Wang CC, Chung YH, Wang YH, Su MC, Huang KT, Chen HC, Lin MC. Chen YM, et al. Among authors: wang cc, wang yh. Lung Cancer. 2016 Mar;93:47-54. doi: 10.1016/j.lungcan.2016.01.001. Epub 2016 Jan 7. Lung Cancer. 2016. PMID: 26898614
5,235 results